Claim 30% Off Global Market Reports With Code ONLINE30 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

What Is The Projected Valuation Of The Respiratory Biologics Market In The Coming Years?

The market for respiratory biologics has experienced swift growth in past years. Its size is projected to escalate from $6.38 billion in 2024 to $7.41 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 16.1%. The significant enlargement during the historical period can be credited to the escalating prevalence of respiratory ailments, the growing acceptance of personalized medication, the global escalation in healthcare expenditure, heightened awareness and diagnosis rates of respiratory problems, and a burgeoning aged population afflicted with respiratory conditions.

The size of the respiratory biologics market is predicted to witness a rapid escalation in the coming years, predicted to expand to “$13.51 billion in 2029” with a Compound Annual Growth Rate (CAGR) of 16.2%. This anticipated growth within the forecast period can be ascribed to the growing occurrences of asthma and COPD, enhanced acceptance of biologic therapies, increased R&D investments, rising demand for non-coda drug delivery, and the broadening of reimbursement policies. Noteworthy trends expected to dominate the forecast period include the usage of monoclonal antibodies for treating respiratory ailments, improvements in biologic drug formulas and their delivery mechanisms, obtaining regulatory consents, strategic alliances and takeovers among leading players, as well as the integration of artificial intelligence in the discovery and production of drugs.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23497&type=smp

Which Market Dynamics Are Playing A Critical Role In The Growth Of The Respiratory Biologics Market?

The escalating levels of air pollution are expected to fuel the expansion of the respiratory biologics market in the future. The term air pollution denotes the existence of detrimental elements such as gases, microscopic matter, and biological molecules in the Earth’s atmosphere, which can adversely affect human health and the environment. The rise in industrialization and urbanization lead to an increase in air pollution, as the emission of pollutants from production units, vehicles, and building activities increases. Respiratory biologics are useful in countering the health consequences of air pollution as they offer specialized therapies that decrease inflammation and enhance lung function in people exposed to airborne contaminants. For example, the Environmental Protection Agency, a US government agency, revealed in January 2025 that over 66 million tons of pollutants were emitted into the atmosphere in the United States in 2023. Additionally, as per the United Nations Environment Programme, a Kenya-based environmental authority, in September 2022, air pollution causes 7 million premature deaths each year, and 99% of the world’s population inhales polluted air. Consequently, the escalation in air pollution is spurring the expansion of the respiratory biologics market.

What Are The Key Segment Trends Observed In The Respiratory Biologics Market?

The respiratory biologics market covered in this report is segmented –

1) By Disease Indication: Asthma, Chronic Rhinosinasitis, Hypereosinophilic Syndrome

2) By Route Of Administration: Intravenous, Subcuteneous

3) By Sales Channel: Hospitals, Specialty Clinics, Retail Pharmacies, Mail Order Pharmacies

Subsegments:

1) By Asthma: Severe Eosinophilic Asthma, Allergic Asthma, Non-Allergic Asthma

2) By Type: Chronic Rhinosinusitis: Chronic Rhinosinusitis with Nasal Polyps, Chronic Rhinosinusitis without Nasal Polyps

3) By Hypereosinophilic Syndrome (HES): Idiopathic HES, Lymphocytic Variant HES, Myeloproliferative HES

Which Disruptive Trends Are Driving Change Across The Respiratory Biologics Market?

Leading firms in the respiratory biologics market are concentrating their efforts on crafting innovative biologic therapies such as targeted immune therapies for chronic respiratory diseases. These specialized treatments are designed to modulate the body’s defense mechanism reducing inflammation and enhancing lung function. A notable example of such advancements is Sanofi S.A., a French-based pharmaceutical firm, which publicized in September 2024 that the US Food and Drug Administration (FDA) gave the green light to Dupixent (dupilumab). This is an add-on maintenance therapy for adults grappling with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype. This authorization sets a pivotal precedent as Dupixent is the premier biologic medicine approved in the US specifically for this category of COPD patients.

Which Firms Are Driving Innovation Within The Respiratory Biologics Market?

Major companies operating in the respiratory biologics market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Amgen Inc., Viatris Inc., Regeneron Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Biogen Inc., Vertex Pharmaceuticals Incorporated, Swedish Orphan Biovitrum AB, Glenmark Pharmaceuticals Ltd., Zymeworks Inc., Kiniksa Pharmaceuticals Ltd., Pieris Pharmaceuticals Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/respiratory-biologics-global-market-report

What Regional Factors Are Accelerating Growth In The Respiratory Biologics Market?

North America was the largest region in the respiratory biologics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the respiratory biologics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=23497&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model